$QTRX
Quanterix Corp Stock $qtrx

$qtrx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000155837021002469 Filed on March 05, 2021

Income Statement

Concept	2020 Q4	2020 Q2	2020 Q1
Revenue	$26.13M	$13.13M	$15.73M
YoY Change	64.17%	-3.0%	27.48%
Cost Of Revenue	$11.08M	$7.917M	$8.914M
YoY Change	22.41%	19.86%	40.82%
Gross Profit	$15.05M	$5.213M	$6.813M
YoY Change	119.23%	-24.79%	13.42%
Gross Profit Margin	57.59%	39.7%	43.32%
Selling, General & Admin	$18.77M	$13.10M	$14.27M
YoY Change	34.49%	-2.44%	23.98%
% of Gross Profit	124.69%	251.33%	209.5%
Research & Development	$6.217M	$4.312M	$4.268M
YoY Change	41.36%	7.37%	10.8%
% of Gross Profit	41.31%	82.72%	62.64%
Depreciation & Amortization	$1.120M	$1.030M	$1.050M
YoY Change	36.59%	90.74%	156.1%
% of Gross Profit	7.44%	19.76%	15.41%
Operating Expenses	$24.98M	$17.41M	$18.54M
YoY Change	36.14%	-0.18%	20.68%
Operating Profit	-$9.933M	-$12.20M	-$11.73M
YoY Change	-13.52%	16.05%	25.34%
Interest Expense	-$170.0K	-$110.0K	$160.0K
YoY Change	-160.71%	-375.0%	700.0%
% of Operating Profit
Other Income/Expense, Net	$155.0K	-$11.00K	-$167.0K
YoY Change	11.51%	-83.82%	255.32%
Pretax Income	-$9.944M	-$12.32M	-$11.73M
YoY Change	-10.13%	16.89%	25.06%
Income Tax	-$123.0K	-$18.00K	-$124.0K
% Of Pretax Income
Net Earnings	-$9.821M	-$12.30M	-$11.61M
YoY Change	-10.38%	16.46%	23.44%
Net Earnings / Revenue	-37.58%	-93.69%	-73.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.31	-$0.43	-$0.41
COMMON SHARES
Basic Shares Outstanding	31.70M	28.31M	28.18M
Diluted Shares Outstanding	31.70M	28.31M	28.18M

Balance Sheet

Concept	2020 Q4	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.6M	$88.80M	$96.40M
YoY Change	66.3%	23.33%	183.53%
Cash & Equivalents	$181.6M	$88.81M	$96.36M
Short-Term Investments
Other Short-Term Assets	$6.000M	$2.100M	$2.700M
YoY Change	185.71%	-12.5%	8.0%
Inventory	$14.86M	$13.79M	$11.40M
Prepaid Expenses
Receivables	$17.18M	$9.526M	$12.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$219.6M	$114.2M	$122.5M
YoY Change	65.54%	23.63%	137.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.91M	$12.35M	$24.20M
YoY Change	15.48%	2.09%	181.4%
Goodwill	$10.46M	$9.390M
YoY Change	11.84%
Intangibles	$13.72M	$13.31M
YoY Change	-4.13%
Long-Term Investments
YoY Change
Other Assets	$357.0K	$529.0K	$1.500M
YoY Change	-35.91%	-66.94%	-6.25%
Total Long-Term Assets	$51.44M	$48.70M	$47.80M
YoY Change	37.95%	186.48%	248.91%
TOTAL ASSETS
Total Short-Term Assets	$219.6M	$114.2M	$122.5M
Total Long-Term Assets	$51.44M	$48.70M	$47.80M
Total Assets	$271.0M	$162.9M	$170.3M
YoY Change	59.48%	48.94%	161.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.799M	$4.878M	$4.700M
YoY Change	17.69%	39.37%	23.68%
Accrued Expenses	$16.90M	$8.700M	$7.700M
YoY Change	85.71%	6.1%	6.94%
Deferred Revenue	$5.421M	$5.019M
YoY Change	15.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.673M	$0.00	$0.00
YoY Change	10130.67%	-100.0%	-100.0%
Total Short-Term Liabilities	$39.80M	$18.90M	$18.00M
YoY Change	100.69%	11.16%	8.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$7.630M	$7.600M
YoY Change	-100.0%	1.73%	0.0%
Other Long-Term Liabilities	$2.649M	$2.537M	$25.60M
YoY Change	-80.24%	-74.88%	276.47%
Total Long-Term Liabilities	$2.649M	$10.17M	$33.20M
YoY Change	-87.38%	-42.23%	130.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.80M	$18.90M	$18.00M
Total Long-Term Liabilities	$2.649M	$10.17M	$33.20M
Total Liabilities	$64.92M	$51.91M	$51.30M
YoY Change	57.22%	49.59%	65.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$247.8M	-$240.2M
YoY Change	14.58%
Common Stock	$451.5M	$351.2M
YoY Change	30.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$206.1M	$111.0M	$119.0M
YoY Change
Total Liabilities & Shareholders Equity	$271.0M	$162.9M	$170.3M
YoY Change	59.48%	48.94%	161.2%

Cashflow Statement

Concept	2020 Q4	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$9.821M	-$12.30M	-$11.61M
YoY Change	-10.38%	16.46%	23.44%
Depreciation, Depletion And Amortization	$1.120M	$1.030M	$1.050M
YoY Change	36.59%	90.74%	156.1%
Cash From Operating Activities	$4.650M	-$7.420M	-$13.18M
YoY Change	-202.42%	-0.67%	146.34%
INVESTING ACTIVITIES
Capital Expenditures	-$1.780M	-$930.0K	$426.0K
YoY Change	223.64%	-76.21%	-107.2%
Acquisitions
YoY Change
Other Investing Activities	$3.300M
YoY Change
Cash From Investing Activities	$1.520M	-$930.0K	-$426.0K
YoY Change	-376.36%	-76.21%	-92.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.080M	620.0K	861.0K
YoY Change	184.93%	-98.75%	3.73%
NET CHANGE
Cash From Operating Activities	4.650M	-7.420M	-13.18M
Cash From Investing Activities	1.520M	-930.0K	-426.0K
Cash From Financing Activities	2.080M	620.0K	861.0K
Net Change In Cash	8.250M	-7.730M	-12.74M
YoY Change	-289.22%	-120.31%	22.07%
FREE CASH FLOW
Cash From Operating Activities	$4.650M	-$7.420M	-$13.18M
Capital Expenditures	-$1.780M	-$930.0K	$426.0K
Free Cash Flow	$6.430M	-$6.490M	-$13.61M
YoY Change	-261.15%	82.3%	-2486.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001503274
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Registrant Name EntityRegistrantName	Quanterix Corp
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31796544
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28112201
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	600000
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38319
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8957988
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Middlesex Turnpike
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Billerica
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01821
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	301-9400
CY2020	dei	Security12g Title Security12gTitle	Common Stock, $0.001 par value per share
CY2020	dei	Trading Symbol TradingSymbol	QTRX
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	7673000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	75000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1234000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3054000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	216000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39803000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19833000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	577000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	466000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7587000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21891000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2649000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13407000
CY2020Q4	us-gaap	Liabilities Liabilities	64920000
CY2019Q4	us-gaap	Liabilities Liabilities	41293000
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020	qtrx	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	234000000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	36267609
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181584000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109155000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	370000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	162000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	172000
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	186000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17184000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10906000
CY2020Q4	us-gaap	Inventory Net InventoryNet	14856000
CY2019Q4	us-gaap	Inventory Net InventoryNet	10463000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5981000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2137000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	219605000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	132661000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1026000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13912000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12047000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13716000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14307000
CY2020Q4	us-gaap	Goodwill Goodwill	10460000
CY2019Q4	us-gaap	Goodwill Goodwill	9353000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11995000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	357000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	557000
CY2020Q4	us-gaap	Assets Assets	271045000
CY2019Q4	us-gaap	Assets Assets	169951000
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	14000
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	36000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6799000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5777000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	10777000
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	6570000
CY2020Q4	qtrx	Other Accrued Liabilities Related Parties Current OtherAccruedLiabilitiesRelatedPartiesCurrent	1377000
CY2019Q4	qtrx	Other Accrued Liabilities Related Parties Current OtherAccruedLiabilitiesRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4845000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2498000
CY2020Q4	qtrx	Deferred Revenue Related Parties Current DeferredRevenueRelatedPartiesCurrent	90000
CY2019Q4	qtrx	Deferred Revenue Related Parties Current DeferredRevenueRelatedPartiesCurrent	55000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5421000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4697000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31796544
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28112201
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	32000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	28000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	451433000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	345027000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2434000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-153000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247774000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216244000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	206125000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	128658000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	271045000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169951000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86377000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56734000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37632000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	38195000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	29898000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	19684000
CY2020	us-gaap	Gross Profit GrossProfit	48182000
CY2019	us-gaap	Gross Profit GrossProfit	26836000
CY2018	us-gaap	Gross Profit GrossProfit	17948000
CY2020	qtrx	Related Party Amount In Research And Development Expenses RelatedPartyAmountInResearchAndDevelopmentExpenses	268000
CY2019	qtrx	Related Party Amount In Research And Development Expenses RelatedPartyAmountInResearchAndDevelopmentExpenses	0
CY2018	qtrx	Related Party Amount In Research And Development Expenses RelatedPartyAmountInResearchAndDevelopmentExpenses	0
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20174000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16190000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15805000
CY2020	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	36000
CY2019	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0
CY2018	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59592000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52246000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33693000
CY2020	us-gaap	Operating Expenses OperatingExpenses	79766000
CY2019	us-gaap	Operating Expenses OperatingExpenses	68436000
CY2018	us-gaap	Operating Expenses OperatingExpenses	49498000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-31584000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-41600000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-31550000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-273000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	627000
CY2018	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	46000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31906000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40983000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31511000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-376000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-187000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-31530000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40796000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29589132
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25090708
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-31530000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40796000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21994317
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1318000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6219000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-31536000
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.07
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.63
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.43
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-31536000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2587000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-153000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2587000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-153000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28943000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40949000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31536000
CY2020	us-gaap	Profit Loss ProfitLoss	-31530000
CY2019	us-gaap	Profit Loss ProfitLoss	-40796000
CY2018	us-gaap	Profit Loss ProfitLoss	-31536000
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	4312000
CY2019	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	3009000
CY2018	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	1352000
CY2020	qtrx	Inventory Valuation Adjustment Amortization InventoryValuationAdjustmentAmortization	722000
CY2019	qtrx	Inventory Valuation Adjustment Amortization InventoryValuationAdjustmentAmortization	611000
CY2020	qtrx	Right Of Use Asset Amortization RightOfUseAssetAmortization	245000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	10099000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6388000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	4884000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	86000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	89000
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	170000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-171000
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-140000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	14000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6240000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3365000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	983000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3927000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-289000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1828000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5119000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3447000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1603000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-198000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	21000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-267000
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	649000
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	621000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	822000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1101000
CY2020	qtrx	Increase Decrease In Payables For Contract Acquisition Costs IncreaseDecreaseInPayablesForContractAcquisitionCosts	87000
CY2019	qtrx	Increase Decrease In Payables For Contract Acquisition Costs IncreaseDecreaseInPayablesForContractAcquisitionCosts	336000
CY2020	qtrx	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	316000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-488000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	9845000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	835000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-708000
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1849000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23365000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26187000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28721000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3930000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10847000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1518000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	14529000
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	3801000
CY2020	qtrx	Proceeds From Grant For Asset Purchase ProceedsFromGrantForAssetPurchase	3304000
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	150000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-626000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25376000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5454000
CY2018	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	-20000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4019000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2820000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1871000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	888000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	879000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	75000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	50000
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1929000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96236000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	116197000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-78000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72245000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64634000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34253000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110181000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45429000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	79682000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182584000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110181000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45429000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	625000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	656000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	606000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1029000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	164000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	78000
CY2019	qtrx	Noncash Or Part Noncash Acquisition Interest Acquired NoncashOrPartNoncashAcquisitionInterestAcquired	7572000
CY2020Q4	qtrx	Business Combination Consideration Transferred Common Stock Shares BusinessCombinationConsiderationTransferredCommonStockShares	191152
CY2019	qtrx	Capital Expenditures Incurred Included In Noncurrent Liabilities CapitalExpendituresIncurredIncludedInNoncurrentLiabilities	5468000
CY2018	qtrx	Fair Value Of Common Warrants FairValueOfCommonWarrants	196000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181584000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109155000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44429000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1026000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	182584000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	110181000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45429000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	65866000
CY2018	qtrx	Stock Issued During Period Value Stock Options And Vesting Restricted Stock Exercised StockIssuedDuringPeriodValueStockOptionsAndVestingRestrictedStockExercised	1871000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	20000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4884000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-31536000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	41065000
CY2019Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	440000
CY2019	qtrx	Stock Issued During Period Value Stock Options And Vesting Restricted Stock Exercised StockIssuedDuringPeriodValueStockOptionsAndVestingRestrictedStockExercised	2820000
CY2019	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5468000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6388000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	878000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-153000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40796000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	128658000
CY2020	qtrx	Stock Issued During Period Value Stock Options And Vesting Restricted Stock Exercised StockIssuedDuringPeriodValueStockOptionsAndVestingRestrictedStockExercised	4019000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	888000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10099000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-31530000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	206125000
CY2020	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Quanterix Corporation (NASDAQ: QTRX) (the Company) is a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. The Company’s platforms are based on its proprietary digital “Simoa” detection technology. The Company’s Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. These capabilities provide the Company’s customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. The Company is currently focusing on protein detection, but the Company’s Simoa platforms have also demonstrated applicability across other testing applications, including detection of nucleic acids and small molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company launched its first immunoassay platform, the Simoa HD-1, in 2014. The HD-1 is a fully automated immunoassay bead-based platform with multiplexing and custom assay capability, and related assay test kits and consumable materials. The Company launched a second bead-based immunoassay platform (SR-X) in the fourth quarter of 2017 with a more compact footprint than the Simoa HD-1 and less automation designed for lower volume requirements while still allowing multiplexing and custom assay capability. The Company initiated an early-access program for its third instrument (SP-X) on the new Simoa planar array platform in January 2019, with the full commercial launch commencing in April 2019. In July 2019, the Company launched the Simoa HD-X, an upgraded version of the Simoa HD-1 which replaces the HD-1. The HD-X has been designed to deliver significant productivity and operational efficiency improvements, as well as greater user flexibility. The Company began shipping and installing HD-X instruments at customer locations in the third quarter of 2019. The Company also performs research services on behalf of customers to apply the Simoa technology to specific customer needs. The Company's customers are primarily in the research use only market, which includes academic and governmental research institutions, the research and development laboratories of pharmaceutical manufacturers, contract research organizations, and specialty research laboratories. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company acquired Aushon Biosystems, Inc. (Aushon) in January 2018. With the acquisition of Aushon, the Company acquired a CLIA certified laboratory, as well as Aushon’s proprietary sensitive planar array detection technology. Leveraging its proprietary sophisticated Simoa image analysis and data analysis algorithms, the Company further refined this planar array technology to develop the SP-X instrument to provide the same Simoa sensitivity found in its bead-based platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company acquired UmanDiagnostics AB (Uman), a Swedish company located in Umeå, Sweden, in August 2019. The acquisition closed with respect to 95% of the outstanding shares of capital stock of Uman on July 1, 2019 and with respect to the remaining 5% of the outstanding shares of capital stock of Uman on August 1, 2019. Uman supplies neurofilament light (Nf-L) antibodies and ELISA kits, which are widely recognized by researchers and biopharmaceutical and diagnostics companies world-wide as the premier solution for the detection of Nf-L to advance the development of therapeutics and diagnostics for neurodegenerative conditions. With the acquisition of Uman, the Company has secured a long-term source of supply for a critical technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">“At-the-market offering”</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 19, 2019, the Company entered into a Sales Agreement (the Sales Agreement) with Cowen and Company, LLC (Cowen) with respect to an “at-the-market” offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Cowen as its sales agent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 5, 2019, the Company issued approximately 2.2 million shares of common stock at an average stock price of $22.73 per share pursuant to the terms of the Sales Agreement. The “at-the-market” offering resulted in gross proceeds of $49.7 million. The Company incurred $1.7 million in issuance costs associated with the “at-the-market” offering, resulting in net proceeds to the Company of $48.0 million. On August 6, 2020, the Company delivered written notice to Cowen to terminate the Sales Agreement, which termination the parties agreed to make immediately effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Underwritten public offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 8, 2019, the Company entered into an underwriting agreement with J.P. Morgan Securities LLC and SVB Leerink LLC (Leerink), as representatives of the several underwriters, relating to an underwritten public offering of approximately 2.7 million shares of the Company’s common stock, par value $0.001 per share. The underwritten public offering resulted in gross proceeds of $69.0 million. The Company incurred $4.5 million in issuance costs associated with the underwritten public offering, resulting in net proceeds to the Company of $64.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 6, 2020, the Company entered into an underwriting agreement with Leerink and Cowen, as representatives of the several underwriters, relating to an underwritten public offering of approximately 3.0 million shares of the Company’s common stock, par value $0.001 per share. The underwritten public offering resulted in gross proceeds of $97.6 million. The Company incurred $6.2 million in issuance costs associated with the underwritten public offering, resulting in net proceeds to the Company of $91.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recognized annual losses from operations since inception and has an accumulated deficit of $247.8 million at December 31, 2020 and the Company incurred a net loss of $31.5 million, $40.8 million, and $31.5 million for the years ended December 31, 2020, 2019, and 2018, respectively. Prior to the Company’s Initial Public Offering (IPO) in December 2017, the Company had funded its operations principally from issuances of preferred stock, debt financings, grants, product and service sales and development and license agreements. At December 31, 2020, the Company had $181.6 million of unrestricted cash and cash equivalents. The Company expects the current cash balance will be sufficient to fund operations for a period of at least one year from the date the consolidated financial statements are issued. There can be no assurances, however, that no additional funding will be required or that additional funding will be available on terms acceptable to the Company, or at all.</p>
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-247800000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-31500000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40800000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-31500000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181600000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. In making those estimates and assumptions, the Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. The Company’s significant estimates included in the preparation of the consolidated financial statements are related to revenue recognition, fair value of assets acquired and liabilities assumed in acquisitions, valuation allowances recorded against deferred tax assets, and valuation of inventory. Actual results could differ from those estimates.</p>
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6000000.0
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5400000
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P24M
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5400000
CY2020	qtrx	Previously Deferred Revenue Recognized PreviouslyDeferredRevenueRecognized	1200000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5163000
CY2020	qtrx	Contract With Customer Liability Deferral Of Revenue ContractWithCustomerLiabilityDeferralOfRevenue	6955000
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-6120000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	5998000
CY2019Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	335000
CY2020	qtrx	Capitalized Contract Cost Deferral Of Costs To Obtain Contract CapitalizedContractCostDeferralOfCostsToObtainContract	506000
CY2020	qtrx	Capitalized Contract Cost Recognition Of Costs To Obtain Contract CapitalizedContractCostRecognitionOfCostsToObtainContract	-593000
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	248000
CY2020	us-gaap	Revenue Practical Expedient Remaining Performance Obligation RevenuePracticalExpedientRemainingPerformanceObligation	true
CY2020	us-gaap	Revenue Practical Expedient Financing Component RevenuePracticalExpedientFinancingComponent	true
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3022432
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2926991
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2914420
CY2020Q4	us-gaap	Cash Cash	19535000
CY2019Q4	us-gaap	Cash Cash	6406000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	162049000
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	102749000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	181584000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109155000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1100000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1100000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1100000
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1000000.0
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1100000
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	36000
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	36000
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	160000
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	34000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	162000
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	493000
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	285000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	370000
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	162048000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	162048000
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	102749000
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	102749000
CY2020	us-gaap	Guarantees Indemnifications And Warranties Policies GuaranteesIndemnificationsAndWarrantiesPolicies	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Warranties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company provides a one-year warranty and maintenance service related to its instruments and sells extended warranty contracts for additional periods. The Company defers revenue associated with these services and recognizes them on a pro-rata basis over the period of service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p>
CY2020	qtrx	Warranty Contract WarrantyContract	P1Y
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.66
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.09
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.19
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6792000
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6839000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10906000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2330000
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2618000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2137000
CY2018Q4	us-gaap	Other Assets OtherAssets	536000
CY2019Q1	us-gaap	Other Assets OtherAssets	555000
CY2019Q4	us-gaap	Other Assets OtherAssets	557000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5437000
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5394000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4697000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216244000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	29898000
CY2019	us-gaap	Gross Profit GrossProfit	26836000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52246000
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	520000
CY2019Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	477000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	466000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175888000
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175448000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40796000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13912000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12047000
CY2020	us-gaap	Depreciation Depreciation	2200000
CY2019	us-gaap	Depreciation Depreciation	1600000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	5265000
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	4717000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3306000
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2573000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6285000
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3173000
CY2020Q4	us-gaap	Inventory Net InventoryNet	14856000
CY2019Q4	us-gaap	Inventory Net InventoryNet	10463000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20348000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16386000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6436000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4339000
CY2020Q4	qtrx	Accrued Inventory AccruedInventory	527000
CY2019Q4	qtrx	Accrued Inventory AccruedInventory	459000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1845000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	476000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	797000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	655000
CY2020Q4	qtrx	Accrued Development Costs AccruedDevelopmentCosts	323000
CY2019Q4	qtrx	Accrued Development Costs AccruedDevelopmentCosts	151000
CY2020Q4	qtrx	Accrued Other Cost AccruedOtherCost	1353000
CY2019Q4	qtrx	Accrued Other Cost AccruedOtherCost	757000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4845000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2498000
CY2019Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	7572000
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3009000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2649000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2825000
CY2019Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2649000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13407000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-29896000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-40010000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-31436000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2010000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-973000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-75000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31906000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	20000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40983000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31511000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	18000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	102000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	93000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	115000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	113000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	18000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	8000
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-502000
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-304000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-491000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-300000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-376000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-187000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-400000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-200000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0.0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.060
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.016
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.023
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.027
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.052
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.023
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.009
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.012
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.004
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	61000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2648000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2825000
CY2020	qtrx	Effective Income Tax Rate Reconciliation Deferred Tax Rate Changes EffectiveIncomeTaxRateReconciliationDeferredTaxRateChanges	0.003
CY2019	qtrx	Effective Income Tax Rate Reconciliation Deferred Tax Rate Changes EffectiveIncomeTaxRateReconciliationDeferredTaxRateChanges	-0.014
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.297
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.246
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.299
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.014
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.012
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020	qtrx	Effective Income Tax Rate Reconciliation Tax Due At International Rate Percent EffectiveIncomeTaxRateReconciliationTaxDueAtInternationalRatePercent	0.012
CY2020	qtrx	Effective Income Tax Rate Reconciliation Impact Of Acquisition Percent EffectiveIncomeTaxRateReconciliationImpactOfAcquisitionPercent	0.210
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	50233000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	43814000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5101000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5518000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2167000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1247000
CY2020Q4	qtrx	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	1054000
CY2019Q4	qtrx	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	928000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1956000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	973000
CY2019Q4	qtrx	Deferred Tax Assets Deferred Rent DeferredTaxAssetsDeferredRent	727000
CY2019Q4	qtrx	Deferred Tax Assets Lease Incentive Obligation DeferredTaxAssetsLeaseIncentiveObligation	1828000
CY2020Q4	qtrx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5703000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2533000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1325000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68747000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56360000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63609000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54137000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5138000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2223000
CY2020Q4	qtrx	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2957000
CY2020Q4	qtrx	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	1775000
CY2019Q4	qtrx	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	1769000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	2880000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	3031000
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	64000
CY2019Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	212000
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	49000
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill	31000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54137000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44033000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9472000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10104000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63609000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54137000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9500000
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	199300000
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	4500000
CY2020	qtrx	Cumulative Change In Ownership Related To Percentage Points CumulativeChangeInOwnershipRelatedToPercentagePoints	0.05
CY2020	qtrx	Percentage Points Related To Ownership Change PercentagePointsRelatedToOwnershipChange	0.50
CY2020	qtrx	Rolling Period Duration Of Ownership Change RollingPeriodDurationOfOwnershipChange	P3Y
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	1559108
CY2019Q4	us-gaap	Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance	882715
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4581540
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3809706
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	10000
CY2019Q3	qtrx	Warrants And Rights Exercised WarrantsAndRightsExercised	66041
CY2019Q3	qtrx	Stock Issued During Period Shares Exercise Of Common Stock Warrants StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants	45690
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10099000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6388000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4884000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.19
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2663000
CY2020	us-gaap	Lease Cost LeaseCost	2663000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2108000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0973
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	4800000
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3300000
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3388000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3466000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3515000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3577000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	22203000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	36149000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13024000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23125000
CY2020Q4	qtrx	Amount Payable To Counterparty AmountPayableToCounterparty	11700000
CY2020	qtrx	Minimum Number Of Commercial Units Purchase Period MinimumNumberOfCommercialUnitsPurchasePeriod	P7Y
CY2020	qtrx	Minimum Number Of Commercial Units Purchase Period MinimumNumberOfCommercialUnitsPurchasePeriod	P7Y
CY2020	qtrx	Termination Of Agreement Supply Warrants To Be Issued Number TerminationOfAgreementSupplyWarrantsToBeIssuedNumber	93341
CY2020	qtrx	Termination Of Agreement Supply Warrants To Be Issued Value Per Share TerminationOfAgreementSupplyWarrantsToBeIssuedValuePerShare	0.003214
CY2020	qtrx	End Of Term Fee EndOfTermFee	50000000
CY2019Q2	qtrx	Debt Instrument Principal Payment Installment DebtInstrumentPrincipalPaymentInstallment	4
CY2020Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7688000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	7688000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	200000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000.0
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2700000
CY2020	qtrx	Previously Deferred Revenue Recognized PreviouslyDeferredRevenueRecognized	1200000
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	500000
CY2019Q4	us-gaap	Deferred Revenue DeferredRevenue	1700000
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	57597000
CY2018	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	38753000
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-38636000
CY2018	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-33894000
CY2020Q4	us-gaap	Goodwill Goodwill	10500000
CY2019Q4	us-gaap	Goodwill Goodwill	9353000
CY2020	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	1107000
CY2020Q4	us-gaap	Goodwill Goodwill	10460000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16400000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4101000
CY2020Q4	qtrx	Cumulative Translations Adjustments Finite Lived Intangible Assets Acquired CumulativeTranslationsAdjustmentsFiniteLivedIntangibleAssetsAcquired	1417000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13716000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16400000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1991000
CY2019Q4	qtrx	Cumulative Translations Adjustments Finite Lived Intangible Assets Acquired CumulativeTranslationsAdjustmentsFiniteLivedIntangibleAssetsAcquired	-102000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14307000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2013000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1930000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1848000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1733000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6192000
CY2020Q4	qtrx	Finite Lived Intangible Assets Net Including Cumulative Translation Adjustments FiniteLivedIntangibleAssetsNetIncludingCumulativeTranslationAdjustments	13716000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000.0
CY2020Q4	qtrx	Letter Of Credit Reduced At41 Months After Commencement Date LetterOfCreditReducedAt41MonthsAfterCommencementDate	750000
CY2020Q4	qtrx	Letter Of Credit Reduced At65 Months After Commencement Date LetterOfCreditReducedAt65MonthsAfterCommencementDate	250000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1000000.0
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26131000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86377000
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15727000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13130000
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31389000
CY2020Q1	us-gaap	Cost Of Revenue CostOfRevenue	8914000
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	7917000
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	10283000
CY2020Q4	us-gaap	Cost Of Revenue CostOfRevenue	11081000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	38195000
CY2020Q1	us-gaap	Gross Profit GrossProfit	6813000
CY2020Q2	us-gaap	Gross Profit GrossProfit	5213000
CY2020Q3	us-gaap	Gross Profit GrossProfit	21106000
CY2020Q4	us-gaap	Gross Profit GrossProfit	15050000
CY2020	us-gaap	Gross Profit GrossProfit	48182000
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4268000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4312000
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5377000
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6217000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20174000
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14273000
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13102000
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13451000
CY2020Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18766000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59592000
CY2020Q1	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	18541000
CY2020Q2	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	17414000
CY2020Q3	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	18828000
CY2020Q4	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	24983000
CY2020	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	79766000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11728000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12201000
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2278000
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9933000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-31584000
CY2020Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	161000
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-108000
CY2020Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-160000
CY2020Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-166000
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-273000
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-167000
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000
CY2020Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	155000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-49000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11734000
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12320000
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2092000
CY2020Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9944000
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-111000
CY2020Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-123000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-376000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-31906000
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-124000
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-11610000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-12302000
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	2203000
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9821000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-31530000
CY2020Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.41
CY2020Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.43
CY2020Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.07
CY2020Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.31
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.07
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28179132
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28312925
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30139157
CY2020Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31696002
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29589132
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
CY2020Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28179132
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28312925
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31386439
CY2020Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31696002
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29589132
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12337000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13536000
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14944000
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15917000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56734000
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	6330000
CY2019Q2	us-gaap	Cost Of Revenue CostOfRevenue	6605000
CY2019Q3	us-gaap	Cost Of Revenue CostOfRevenue	7911000
CY2019Q4	us-gaap	Cost Of Revenue CostOfRevenue	9052000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	29898000
CY2019Q1	us-gaap	Gross Profit GrossProfit	6007000
CY2019Q2	us-gaap	Gross Profit GrossProfit	6931000
CY2019Q3	us-gaap	Gross Profit GrossProfit	7033000
CY2019Q4	us-gaap	Gross Profit GrossProfit	6865000
CY2019	us-gaap	Gross Profit GrossProfit	26836000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3852000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4016000
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3924000
CY2019Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13953000
CY2019Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4398000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16190000
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11512000
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13429000
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13352000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52246000
CY2019Q1	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	15364000
CY2019Q2	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	17445000
CY2019Q3	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	17276000
CY2019Q4	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	18351000
CY2019	qtrx	Total Cost Of Revenues And Operating Expenses TotalCostOfRevenuesAndOperatingExpenses	68436000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9357000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10514000
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10243000
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-11486000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-41600000
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	21000
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	42000
CY2019Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	282000
CY2019Q4	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	282000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	627000
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-47000
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-34000
CY2019Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	139000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9383000
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10540000
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9995000
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11065000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40983000
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-125000
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-107000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-187000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9405000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-10563000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-9870000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-10958000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-40796000
CY2019Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.42
CY2019Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.46
CY2019Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.37
CY2019Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.39
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.63
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22422960
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23213653
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	26627831
CY2019Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28021957
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25090708

Files In Submission

Name	View Source	Status
0001558370-21-002469-index-headers.html	Edgar Link	pending
0001558370-21-002469-index.html	Edgar Link	pending
0001558370-21-002469.txt	Edgar Link	pending
0001558370-21-002469-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tmb-20201231.xsd	Edgar Link	pending
tmb-20201231x10k.htm	Edgar Link	pending
tmb-20201231x10k001.jpg	Edgar Link	pending
tmb-20201231x10k002.jpg	Edgar Link	pending
tmb-20201231x10k003.jpg	Edgar Link	pending
tmb-20201231x10k004.jpg	Edgar Link	pending
tmb-20201231x10k005.jpg	Edgar Link	pending
tmb-20201231x10k006.jpg	Edgar Link	pending
tmb-20201231x10k007.jpg	Edgar Link	pending
tmb-20201231x10k009.jpg	Edgar Link	pending
tmb-20201231x10k010.jpg	Edgar Link	pending
tmb-20201231x10k011.jpg	Edgar Link	pending
tmb-20201231x10k012.gif	Edgar Link	pending
tmb-20201231x10k013.jpg	Edgar Link	pending
tmb-20201231x10k014.jpg	Edgar Link	pending
tmb-20201231x10k015.jpg	Edgar Link	pending
tmb-20201231x10k016.jpg	Edgar Link	pending
tmb-20201231x10k017.jpg	Edgar Link	pending
tmb-20201231x10k018.jpg	Edgar Link	pending
tmb-20201231x10k019.jpg	Edgar Link	pending
tmb-20201231x10k020.jpg	Edgar Link	pending
tmb-20201231x10k021.jpg	Edgar Link	pending
tmb-20201231x10k022.jpg	Edgar Link	pending
tmb-20201231x10k023.jpg	Edgar Link	pending
tmb-20201231x10k_htm.xml	Edgar Link	completed
tmb-20201231xex21d1.htm	Edgar Link	pending
tmb-20201231xex23d1.htm	Edgar Link	pending
tmb-20201231xex31d1.htm	Edgar Link	pending
tmb-20201231xex31d2.htm	Edgar Link	pending
tmb-20201231xex32d1.htm	Edgar Link	pending
tmb-20201231_cal.xml	Edgar Link	unprocessable
tmb-20201231_def.xml	Edgar Link	unprocessable
tmb-20201231_lab.xml	Edgar Link	unprocessable
tmb-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QTRX
Quanterix Corp Stock $qtrx

2020 Q4 Form 10-K Financial Statement

#000155837021002469 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QTRX Quanterix Corp Stock $qtrx

2020 Q4 Form 10-K Financial Statement

#000155837021002469 Filed on March 05, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QTRX
Quanterix Corp Stock $qtrx